
Colossal targets $20B+ valuation to fuel mammoth revival and other deeptech ambitions
Colossal Biosciences is pursuing a fundraising round expected to value the company at $20–$30 billion as it moves from pre-revenue to revenue, advancing de-extinction and synthetic biology efforts such as hatching chicks from artificial eggs and pursuing an artificial mammal womb; it collaborates on genetic vaults with the U.S. government and Dubai's Museum of the Future and has spun off Breaking (plastic degradation) and Form Bio (DNA analytics), all amid a booming deeptech scene and ongoing ecological-risk criticism; Colossal did not comment.













